Overcoming diagnostic issues in precision treatment of pancreatic cancer

References

• Löhr JM. Personal view: pancreatic cancer should be treated as a medical emergency. BMJ. 2014;349:g5261.
   PubMedGoogle Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016;55(910):1158–1160.
   PubMedGoogle Scholar
• Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.
   PubMed Web of Science ®Google Scholar
• Sefrioui D, Blanchard F, Toure E, et al. Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer. 2017;117(7):1017–1025.
   PubMed Web of Science ®Google Scholar
• Neesse A, Algül H, Tuveson DA, et al. Stromal biology and therapy in pancreatic cancer: a changing paradigm. GUT. 2015;64(9):1476–1484.
   PubMed Web of Science ®Google Scholar
• Tuveson DA, Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell. 2012;148(12):21–23.
   PubMedGoogle Scholar
• Li Y, Ahmad A, Banerjee S, et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nature reviews. Gastroenterology & Hepatology. 2011;8(1):27–33.
   Google Scholar
• Sohal DP, Fesinmeyer MD, Timofeeva M, et al. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106(3):dju011.
   PubMedGoogle Scholar
• Waddell N, Pajic M, Patch A-M, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501.
   PubMed Web of Science ®Google Scholar
• Gore J, Korc M. Pancreatic cancer stroma: friend or foe? Cancer Cell. 2014;25(6):711–712.
   PubMed Web of Science ®Google Scholar
• Koay EJ, Amer AM, Baio FE, et al. Toward stratification of patients with pancreatic cancer: past lessons from traditional approaches and future applications with physical biomarkers. Cancer Lett. 2016;381(1):237–243.
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–1806.
   PubMed Web of Science ®Google Scholar
• Deinzer M, Faissner R, Metzger T, et al. Comparison of two different methods for CA19-9 antigen determination. Clin Lab. 2010;56(78):319–325.
   PubMedGoogle Scholar
• Chiorean EG, Von Hoff DD, Tabernero J, et al. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer. 2016;115(2):188–194.
   PubMed Web of Science ®Google Scholar
• Notta F, Hahn SA, Real FX. A genetic roadmap of pancreatic cancer: still evolving. GUT. 2017;66(12):2170–2178.
   PubMed Web of Science ®Google Scholar
• Tempero MA, Klimstra D, Berlin J, et al. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res. 2013;19(3):538–540.
   PubMed Web of Science ®Google Scholar
• Le N, Sund M, Vinci A. Prognostic and predictive markers in pancreatic adenocarcinoma. Dig Liver Dis. 2016;48(3):223–230.
   PubMedGoogle Scholar
• Pihlak R, Valle JW, McNamara MG. Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget. 2017;8(42):73240–73257.
   PubMedGoogle Scholar
• Golan T, Javle M. DNA repair dysfunction in pancreatic cancer: a clinically relevant subtype for drug development. J Natl Compr Canc Netw. 2017;15(8):1063–1069.
   PubMed Web of Science ®Google Scholar
• Del Chiaro M, Verbeke CS, Kartalis N, et al. Short-term results of a magnetic resonance imaging-based swedish screening program for individuals at risk for pancreatic cancer. JAMA Surg. 2015;150(6):512.
   PubMed Web of Science ®Google Scholar
• Löhr M, Müller P, Mora J, et al. p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitis. Gastrointest Endosc. 2001;53(7):734–743.
   PubMed Web of Science ®Google Scholar
• Ako S, Nouso K, Kinugasa H, et al. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. Pancreatology. 2017;17(2):285–290.
   PubMed Web of Science ®Google Scholar
• Court CM, Ankeny JS, Sho S, et al. Reality of single circulating tumor cell sequencing for molecular diagnostics in pancreatic cancer. J Mol Diagn. 2016;18(5):688–696.
   PubMed Web of Science ®Google Scholar
• Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546(7659):498–503.
   PubMed Web of Science ®Google Scholar
• Yang S, Che SPY, Kurywchak P, et al. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. Cancer Biol Ther. 2017;18(3):158–165.
   PubMed Web of Science ®Google Scholar
• Allenson K, Castillo J, San Lucas FA, et al. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol. 2017;28(4):741–747.
   PubMed Web of Science ®Google Scholar
• Malgerud L, Lindberg J, Wirta V, et al. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Mol Oncol. 2017;11(10):1413–1429.
   PubMed Web of Science ®Google Scholar
• Baumgart M, Pandya K. The use of biomarkers in the treatment of non-small cell lung cancer. Exp Rev Prec Med Drug Devel. 2016;1(1):25–36.
   Web of Science ®Google Scholar
• Perez-Gracia JL, Sanmamed MF, Bosch A, et al. Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treat Rev. 2017;53:79–97.
   PubMed Web of Science ®Google Scholar
• Skelton, W.P.t., Parekh H, Starr JS, et al. Clinical factors as a component of the personalized treatment approach to advanced pancreatic cancer: a systematic literature review. J Gastrointest Cancer. 2018 Mar;49(1):1-8. doi: 10.1007/s12029-017-0021-z.
   PubMed Web of Science ®Google Scholar
• Khoja L, Backen A, Sloane R, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer. 2012;106(3):508–516.
   PubMed Web of Science ®Google Scholar
• Sausen M, Phallen J, Adleff V, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015;6(1):7686.
   PubMedGoogle Scholar
• Pietrasz D, Pécuchet N, Garlan F, et al. Plasma circulating tumor dna in pancreatic cancer patients is a prognostic marker. Clin Cancer Res. 2017;23(1):116–123.
   PubMed Web of Science ®Google Scholar
• Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–182.
   PubMed Web of Science ®Google Scholar
• Imamura T, Komatsu S, Ichikawa D, et al. Liquid biopsy in patients with pancreatic cancer: circulating tumor cells and cell-free nucleic acids. World J Gastroenterol. 2016;22(25):5627–5641.
   PubMed Web of Science ®Google Scholar
• Gulbahce N, Magbanua MJM, Chin R, et al. Quantitative whole genome sequencing of circulating tumor cells enables personalized combination therapy of metastatic cancer. Cancer Res. 2017;77(16):4530–4541.
   PubMed Web of Science ®Google Scholar
• Pimienta M, Edderkaoui M, Wang R, et al. The potential for circulating tumor cells in pancreatic cancer management. Front Physiol. 2017;8:381.
   PubMed Web of Science ®Google Scholar
• Han L, Chen W, Zhao Q. * Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Tumour Biol. 2014;35(3):2473–2480.
   PubMedGoogle Scholar
• Sho S, Court CM, Winograd P, et al. Precision oncology using a limited number of cells: optimization of whole genome amplification products for sequencing applications. BMC Cancer. 2017;17(1):457.
   PubMedGoogle Scholar
• Holley T, Lenkiewicz E, Evers L, et al. Deep clonal profiling of formalin fixed paraffin embedded clinical samples. PLoS ONE. 2012;7(11):e50586.
   PubMed Web of Science ®Google Scholar
• Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–1031.
   PubMed Web of Science ®Google Scholar
• Young G, Wang K, He J, et al. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol. 2013;121(12):688–694.
   PubMed Web of Science ®Google Scholar
• Aziz N, Zhao Q, Bry L, et al. College of American Pathologists’ laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med. 2015 Apr;139(4):481-93. doi: 10.5858/arpa.2014-0250-CP.
   Web of Science ®Google Scholar
• Hagemann IS, Cottrell CE, Lockwood CM. Design of targeted, capture-based, next generation sequencing te sts for precision cancer therapy. Cancer Genet. 2013;206(12):420–431.
   PubMed Web of Science ®Google Scholar
• Jamieson NB, Morran DC, Morton JP, et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res. 2012;18(2):534–545.
   PubMed Web of Science ®Google Scholar
• Frampton AE, Krell J, Jamieson NB, et al. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. Eur J Cancer. 2015;51(11):1389–1404.
   PubMed Web of Science ®Google Scholar
• Hoshikawa M, Aoki T, Matsushita H, et al. NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer. Biochem Biophys Res Commun. 2018;495(2):2058–2065.
   PubMed Web of Science ®Google Scholar
• Feng M, Xiong G, Cao Z, et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer Lett. 2017;407:57–65.
   PubMed Web of Science ®Google Scholar
• Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat Med. 2017;23(9):1028–1035.
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.
   PubMed Web of Science ®Google Scholar
• Iovanna J, Dusetti N. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road. Cancer Lett. 2017;410:63–67.
   PubMed Web of Science ®Google Scholar
• Cancer genome atlas research network. Electronic address, A.A.D.H.E. And cancer genome atlas research N. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32(2):185–203 e13.
   PubMed Web of Science ®Google Scholar
• Gullapalli RR, Santana-Santos L, Gullapalli R, et al. Next generation sequencing in clinical medicine: challenges and lessons for pathology and biomedical informatics. J Pathol Inform. 2012;3:40.
   PubMedGoogle Scholar
• Malgerud L, Lindberg J, Wirta V, et al. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Molecular Oncology. 2017;11(10):1413–1429.
   PubMed Web of Science ®Google Scholar
• Gentzler RD, Yentz SE, Johnson ML, et al. The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria. Cancer. 2014;120(24):3853–3858.
   PubMed Web of Science ®Google Scholar
• Kim Y, Guntupalli SR, Lee SJ, et al. Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer. PLoS ONE. 2014;9(2):e86532.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wen S, Hong DS, et al. Personalized medicine for patients with advanced cancer in the phase i program at md anderson: validation and landmark analyses. Clin Cancer Res. 2014;20(18):4827–4836.
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006.
   PubMed Web of Science ®Google Scholar
• Mardis ER. Applying next-generation sequencing to pancreatic cancer treatment. Nat Rev Gastroenterol Hepatol. 2012;9(8):477–486.
   PubMed Web of Science ®Google Scholar
• Cotterell J. Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient. Onco Targets Ther. 2014;7:655–662.
   PubMed Web of Science ®Google Scholar
• Liang WS, Craig DW, Carpten J, et al. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS ONE. 2012;7(10):e43192.
   PubMed Web of Science ®Google Scholar
• Ellard S, Patrinos GP, Oetting WS. Clinical applications of next-generation sequencing: the 2013 human genome variation society scientific meeting. Hum Mutat. 2013;34(11):1583–1587.
   PubMed Web of Science ®Google Scholar
• Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47(11):1676–1681.
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li C-P, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545–557.
   PubMed Web of Science ®Google Scholar
• Cooperman AM, Bruckner H, Snady H, et al. Cancer of the pancreas-actual 5, 10, and 20+year survival: the lucky and fortunate few. Surg Clin North Am. 2018;98(1):73–85.
   PubMed Web of Science ®Google Scholar
• Löhr JM, Malgerud L, Karimi M, et al. Puzzling cases in pancreatic diseases. In: Löhr JM, ed. Ten year survival with pancreatic adenocarcinoma. Mumbai, India: Kothari Publishing; 2017.
   Google Scholar
• Löhr JM, Lönnebro R, Stigliano S, et al. (2014) Outcome of probe-based confocal laser endomicroscopy (pCLE) during ERCP. A single-center prospective study in 45 patients. submitted
   Google Scholar
• Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov. 2013;12(5):358–369.
   PubMed Web of Science ®Google Scholar
• Zill OA, Greene C, Sebisanovic D, et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discovery. 2015;5(10):1040–1048.
   PubMed Web of Science ®Google Scholar
• El-Heliebi A, Hille C, Laxman N, et al. In situ detection and quantification of AR-V7, AR-FL, PSA, and KRAS point mutations in Circulating Tumor Cells. Clin Chem. 2018;64(3):536–546.
   PubMed Web of Science ®Google Scholar
• Iguchi E, Safgren SL, Marks DL, et al. Pancreatic Cancer, A Mis-interpreter of the Epigenetic Language. The Yale Journal of Biology and Medicine. 2016;89(4):575–590.
   PubMedGoogle Scholar
• Nones K, Waddell N, Song S, et al. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer. 2014;135(5):1110–1118.
   PubMed Web of Science ®Google Scholar
• Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018 Feb 23;359(6378):926-930. doi: 10.1126/science.aar3247.
   PubMed Web of Science ®Google Scholar
• Court CM, Ankeny JS, Hou S, et al. Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis. Expert Rev Mol Diagn. 2015;15(11):1491–1504.
   PubMed Web of Science ®Google Scholar
• Yu M, Ting DT, Stott SL, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012;487(7408):510–513.
   PubMed Web of Science ®Google Scholar
• Ho TH, Dang KX, Lintula S, et al. Extendable blocking probe in reverse transcription for analysis of RNA variants with superior selectivity. Nucleic Acids Res. 2015;43(1):e4.
   PubMed Web of Science ®Google Scholar
• Capdevila J, Rojo F, Gonzalez-Martin A, et al. Molecular profiling for clinical decision making in advanced cancer: a clinical appraisal. J Cancer Res Treatm. 2017;5(3):77–85.
   Google Scholar
• Wrzeszczynski KO, Frank MO, Koyama T, et al. Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma. Neurol Genet. 2017;3(4):e164.
   PubMed Web of Science ®Google Scholar
• Gavan SP, Thompson AJ, Payne K. The economic case for precision medicine. Expert Rev Prec Med Drug Devel. 2018;3(1):1–9.
   PubMed Web of Science ®Google Scholar
• European study group on cystic tumours of the p. European evidence-based guidelines on pancreatic cystic neoplasms. GUT. 2018;67(5):789–804.
   PubMed Web of Science ®Google Scholar
• Biankin AV. The road to precision oncology. Nat Genet. 2017;49(3):320–321.
   PubMed Web of Science ®Google Scholar
• Omazic B, Ayoglu B, Löhr JM, et al. Stem cell transplantation for pancreatic cancer results in long-term survival due to response to novel transplantation-induced antigens. J Immunetherapy. 2017 Mar 23. doi: 10.1097/CJI.0000000000000164.
   Google Scholar
• Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. GUT. 2011;60(3):397–411.
   PubMed Web of Science ®Google Scholar